Patents by Inventor Nathaniel Stephen Wang
Nathaniel Stephen Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240042005Abstract: The present disclosure generally relates to the use of different self-amplifying RNA molecules to enhance immune responses, for example immune responses following prophylactic vaccination or therapeutic administration. Some embodiments relate to compositions and methods for inducing an immune response in a subject using prime-boost immunization regimens.Type: ApplicationFiled: October 23, 2023Publication date: February 8, 2024Inventors: Kurt Iver KAMRUD, Nathaniel Stephen WANG, Parinaz ALIAHMAD, Jason L. DEHART
-
Patent number: 11873507Abstract: The present disclosure relates to the field of molecular virology, and particularly relates to nucleic acid molecules encoding a modified alphavirus virus viral genome or self-replicating RNA (srRNA) construct, pharmaceutical compositions containing the same, and the use of such nucleic acid molecules and compositions for production of desired products in cell cultures or in a living body. Also provided are methods for eliciting a pharmacodynamics effect in a subject.Type: GrantFiled: November 29, 2021Date of Patent: January 16, 2024Assignee: Replicate Bioscience, Inc.Inventors: Nathaniel Stephen Wang, Shigeki Joseph Miyake-Stoner, Parinaz Aliahmad
-
Patent number: 11845939Abstract: The present disclosure generally relates to nucleic acid molecules for use in regulating gene expression. Disclosed herein include nucleic acid molecules containing one or more structural elements of the viral capsid enhancer operably linked to a coding sequence of a gene of interest. In some embodiments, the viral capsid enhancer comprises a Downstream Loop (DLP) from a viral capsid protein, or a variant of the DLP.Type: GrantFiled: December 4, 2017Date of Patent: December 19, 2023Assignee: Janssen Pharmaceuticals, Inc.Inventors: Kurt Iver Kamrud, Maung Nyan Win, Nathaniel Stephen Wang, Jason L. DeHart
-
Publication number: 20230398200Abstract: The present disclosure relates to the field of molecular virology, including nucleic acid molecules comprising modified viral genomes or replicons, pharmaceutical compositions containing the same, and the use of such nucleic acid molecules and compositions for production of desired products in cell cultures or in a living body. Also provided are methods for eliciting an immune response in a subject in need thereof, as well as methods for preventing and/or treating various health conditions.Type: ApplicationFiled: July 30, 2021Publication date: December 14, 2023Inventors: Nathaniel Stephen WANG, Shigeki Joseph MIYAKE-STONER
-
Patent number: 11826416Abstract: The present disclosure generally relates to the use of different self-amplifying RNA molecules to enhance immune responses, for example immune responses following prophylactic vaccination or therapeutic administration. Some embodiments relate to compositions and methods for inducing an immune response in a subject using prime-boost immunization regimens.Type: GrantFiled: July 7, 2021Date of Patent: November 28, 2023Assignee: Janssen Pharmaceuticals, Inc.Inventors: Kurt Iver Kamrud, Nathaniel Stephen Wang, Parinaz Aliahmad, Jason L. Dehart
-
Patent number: 11730804Abstract: The present disclosure relates generally to the field of molecular virology, and particularly relates to nucleic acid molecules encoding a modified alphavirus virus viral genome or self-replicating RNA (srRNA) construct, recombinant cells and pharmaceutical compositions containing the same, as well as the use of such nucleic acid molecules, recombinant cells and compositions for production of desired products in cell cultures or in a living body. Also provided are methods for eliciting an immune response in a subject in need thereof, as well as methods for preventing and/or treating rabies virus infection.Type: GrantFiled: April 13, 2022Date of Patent: August 22, 2023Assignee: Replicate Bioscience, Inc.Inventors: Nathaniel Stephen Wang, Shigeki Joseph Miyake-Stoner, Parinaz Aliahmad, Andrew Geall
-
Publication number: 20230227850Abstract: The present disclosure generally relates to viral-based expression systems suitable for the production of molecule of interests in recombinant host cells. The disclosure particularly relates to nucleic acid constructs, such as expression vectors, containing a modified arterivirus genome or replicon RNA in which at least some of its original viral sequence has been deleted. Also included in the disclosure are viral-based expression vectors including one or more expression cassettes encoding heterologous polypeptides. In some embodiments, the expression cassettes are configured and positioned at defined locations on the viral genome so as to enable expression of the heterologous polypeptides in a tunable manner.Type: ApplicationFiled: January 13, 2023Publication date: July 20, 2023Inventors: Kurt Iver KAMRUD, Nathaniel Stephen WANG, Martina FELDERMAN, Nancy C. CARRICO
-
Publication number: 20230167459Abstract: The present disclosure relates to the field of molecular virology, and particularly relates to nucleic acid molecules encoding a modified alphavirus virus viral genome or self-replicating RNA (srRNA) construct, pharmaceutical compositions containing the same, and the use of such nucleic acid molecules and compositions for production of desired products in cell cultures or in a living body. Also provided are methods for eliciting a pharmacodynamics effect in a subject.Type: ApplicationFiled: November 29, 2021Publication date: June 1, 2023Inventors: Nathaniel Stephen WANG, Shigeki Joseph MIYAKE-STONER, Parinaz ALIAHMAD
-
Patent number: 11555205Abstract: The present disclosure generally relates to viral-based expression systems suitable for the production of molecule of interests in recombinant host cells. The disclosure particularly relates to nucleic acid constructs, such as expression vectors, containing a modified arterivirus genome or replicon RNA in which at least some of its original viral sequence has been deleted. Also included in the disclosure are viral-based expression vectors including one or more expression cassettes encoding heterologous polypeptides. In some embodiments, the expression cassettes are configured and positioned at defined locations on the viral genome so as to enable expression of the heterologous polypeptides in a tunable manner.Type: GrantFiled: December 4, 2019Date of Patent: January 17, 2023Assignee: Janssen Pharmaceuticals, Inc.Inventors: Kurt Iver Kamrud, Nathaniel Stephen Wang, Martina Felderman, Nancy C. Carrico
-
Patent number: 11510975Abstract: The present disclosure relates to the field of molecular virology, and particularly relates to nucleic acid molecules encoding a modified equine encephalitis virus viral genome or self-replicating RNA (srRNA) construct, pharmaceutical compositions containing the same, and the use of such nucleic acid molecules and compositions for production of desired products in cell cultures or in a living body. Also provided are methods for eliciting an immune response in a subject in need thereof, as well as methods for preventing and/or treating cancer.Type: GrantFiled: November 29, 2021Date of Patent: November 29, 2022Assignee: Replicate Bioscience, Inc.Inventors: Nathaniel Stephen Wang, Shigeki Joseph Miyake-Stoner, Parinaz Aliahmad
-
Publication number: 20220016237Abstract: Nucleic acid molecules encoding hepatitis B virus (HBV) surface antigens, HBV core antigens, and HBV polymerase antigens, and related combinations, are described. Also described are vectors, such as DNA plasmids or viral vectors, and RNA replicons, expressing the HBV antigens, and pharmaceutical compositions containing the expression vectors. Methods of inducing an immune response against HBV or treating an HBV-induced disease, particularly in individuals having chronic HBV infection, using the pharmaceutical compositions of the invention are also described.Type: ApplicationFiled: July 8, 2021Publication date: January 20, 2022Inventors: Jason L. DEHART, Nathaniel Stephen WANG, Parinaz ALIAHMAD, Christian MAINE, Heather Lynn DAVIS, Craig PACE
-
Publication number: 20210330781Abstract: The present disclosure generally relates to the use of different self-amplifying RNA molecules to enhance immune responses, for example immune responses following prophylactic vaccination or therapeutic administration. Some embodiments relate to compositions and methods for inducing an immune response in a subject using prime-boost immunization regimens.Type: ApplicationFiled: July 7, 2021Publication date: October 28, 2021Inventors: Kurt Iver KAMRUD, Nathaniel Stephen WANG, Parinaz ALIAHMAD, Jason L. DEHART
-
Patent number: 11083786Abstract: The present disclosure generally relates to the use of different self-amplifying RNA molecules to enhance immune responses, for example immune responses following prophylactic vaccination or therapeutic administration. Some embodiments relate to compositions and methods for inducing an immune response in a subject using prime-boost immunization regimens.Type: GrantFiled: January 18, 2019Date of Patent: August 10, 2021Assignee: JANSSEN PHARMACEUTICALS, INC.Inventors: Kurt Iver Kamrud, Nathaniel Stephen Wang, Parinaz Aliahmad, Jason DeHart
-
Publication number: 20200123573Abstract: The present disclosure generally relates to viral-based expression systems suitable for the production of molecule of interests in recombinant host cells. The disclosure particularly relates to nucleic acid constructs, such as expression vectors, containing a modified arterivirus genome or replicon RNA in which at least some of its original viral sequence has been deleted. Also included in the disclosure are viral-based expression vectors including one or more expression cassettes encoding heterologous polypeptides. In some embodiments, the expression cassettes are configured and positioned at defined locations on the viral genome so as to enable expression of the heterologous polypeptides in a tunable manner.Type: ApplicationFiled: December 4, 2019Publication date: April 23, 2020Inventors: Kurt Iver KAMRUD, Nathaniel Stephen WANG, Martina FELDERMAN, Nancy C. CARRICO
-
Publication number: 20200109178Abstract: The invention provides RNA replicons useful for administering a heterologous protein or peptide into a mammal and eliciting a reduced immune response or no immune response from the mammal. The RNA replicons have RNA sequences encoding for a heterologous protein or peptide, New World alphavirus nonstructural proteins nsP1, nsP2, and nsP4; and an alphavirus nsP3 protein macro domain, central domain, and hypervariable domain. The encoded hypervariable domain can have an amino acid sequence derived from an Old World alphavirus nsP3 hypervariable domain; or can have an amino acid sequence derived from a portion of a New World alphavirus nsP3 hypervariable domain, and another portion derived from an Old World alphavirus nsP3 hypervariable domain.Type: ApplicationFiled: October 8, 2019Publication date: April 9, 2020Inventors: Jason L. DEHART, Nathaniel Stephen WANG, Parinaz ALIAHMAD, Shigeki MIYAKE-STONER, Kurt Iver KAMRUD
-
Patent number: 10538786Abstract: The present disclosure generally relates to viral-based expression systems suitable for the production of molecule of interests in recombinant host cells. The disclosure particularly relates to nucleic acid constructs, such as expression vectors, containing a modified arterivirus genome or replicon RNA in which at least some of its original viral sequence has been deleted. Also included in the disclosure are viral-based expression vectors including one or more expression cassettes encoding heterologous polypeptides. In some embodiments, the expression cassettes are configured and positioned at defined locations on the viral genome so as to enable expression of the heterologous polypeptides in a tunable manner.Type: GrantFiled: April 12, 2017Date of Patent: January 21, 2020Assignee: Janssen Pharmaceuticals, Inc.Inventors: Kurt Iver Kamrud, Nathaniel Stephen Wang, Martina Felderman, Nancy C. Carrico
-
Publication number: 20190224299Abstract: The present disclosure generally relates to the use of different self-amplifying RNA molecules to enhance immune responses, for example immune responses following prophylactic vaccination or therapeutic administration. Some embodiments relate to compositions and methods for inducing an immune response in a subject using prime-boost immunization regimens.Type: ApplicationFiled: January 18, 2019Publication date: July 25, 2019Inventors: Kurt Iver Kamrud, Nathaniel Stephen Wang, Parinaz Aliahmad, Jason DeHart
-
Publication number: 20180171340Abstract: The present disclosure generally relates to nucleic acid molecules for use in regulating gene expression. Disclosed herein include nucleic acid molecules containing one or more structural elements of the viral capsid enhancer operably linked to a coding sequence of a gene of interest. In some embodiments, the viral capsid enhancer comprises a Downstream Loop (DLP) from a viral capsid protein, or a variant of the DLP.Type: ApplicationFiled: December 4, 2017Publication date: June 21, 2018Inventors: Kurt Iver Kamrud, Maung Nyan Win, Nathaniel Stephen Wang, Jason L. DeHart
-
Publication number: 20170314043Abstract: The present disclosure generally relates to viral-based expression systems suitable for the production of molecule of interests in recombinant host cells. The disclosure particularly relates to nucleic acid constructs, such as expression vectors, containing a modified arterivirus genome or replicon RNA in which at least some of its original viral sequence has been deleted. Also included in the disclosure are viral-based expression vectors including one or more expression cassettes encoding heterologous polypeptides. In some embodiments, the expression cassettes are configured and positioned at defined locations on the viral genome so as to enable expression of the heterologous polypeptides in a tunable manner.Type: ApplicationFiled: April 12, 2017Publication date: November 2, 2017Inventors: Kurt Iver Kamrud, Nathaniel Stephen Wang, Martina Felderman, Nancy C. Carrico